PAREXEL International GmbH

At Parexel – Early Phase Clinical Unit Berlin researchers are exploring new therapies for cardiovascular conditions such as chronic heart failure, hypertension and rare arterial disorders. The work focuses on safety, tolerability and drug behavior to broaden treatment options for patients with heart and vascular disease.

• Chronic Heart Failure
• Treatment‑resistant hypertension
• Primary aldosteronism
• Generalized Arterial Calcification of Infancy
• Cardiorenal disease

Early‑phase studies at the Berlin site contribute to a deeper understanding of heart health and support the development of innovative cardiovascular medicines.

Clinical investigations target gastro‑intestinal disorders including obesity‑related metabolic impact and functional conditions such as eosinophilic esophagitis. Researchers evaluate how new agents affect appetite, gastric emptying and overall digestive function to improve patient outcomes.

• Obesity
• Eosinophilic esophagitis
• Chronic rhinosinusitis with nasal polyposis
• Prurigo nodularis
• Atopic dermatitis (related skin‑digestive axis)

The trials aim to identify safe, effective treatments that modulate digestive physiology and support weight management.

Studies are centered on immune‑mediated disorders such as immune thrombocytopenia purpura, rheumatoid arthritis and allergic reactions. The primary goal is to test novel biologics and small molecules for safety and immune response modulation.

• Immune Thrombocytopenia Purpura
• Rheumatoid Arthritis
• Type 1 allergic reactions (including anaphylaxis)
• Inflammation (general)
• Chronic rhinosinusitis with nasal polyposis

Early‑phase work helps determine how emerging immunotherapies can safely alter disease pathways.

The unit conducts research on musculoskeletal conditions such as osteoarthritis, focusing on pain relief and joint function. Trials assess safety and pharmacodynamics of innovative compounds that may slow disease progression.

• Osteoarthritis of the knee
• Joint inflammation
• Musculoskeletal pain
• Mobility impairment
• Bone health biomarkers

Findings support the development of new treatments aimed at improving quality of life for patients with joint disorders.

Research efforts address neurological and respiratory‑linked disorders such as asthma and mild to moderate chronic obstructive pulmonary disease. The studies evaluate how novel inhaled or oral agents affect lung function and symptom control.

• Moderate to severe asthma
• Mild to moderate asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Respiratory disease (general)
• Pulmonary function impairment

By measuring safety and lung exposure, the trials aim to bring better respiratory therapies to patients.

Investigations focus on metabolic health, including body weight management, type 2 diabetes and related metabolic syndromes. The purpose is to test how new molecules influence appetite, glucose control and lipid metabolism.

• Obesity
• Type 2 Diabetes with overweight or obesity
• Body weight management
• Metabolic syndrome
• Appetite regulation

Early‑phase data help determine the safety profile of candidates that could transform metabolic disease treatment.

The Berlin site runs trials on respiratory tract conditions such as COPD, asthma and related airway diseases. Studies assess drug delivery, pharmacokinetics and lung function improvements to guide future therapeutic options.

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma (moderate to severe)
• Chronic rhinosinusitis with nasal polyposis
• Respiratory hyperinflation
• Pulmonary disease (general)

The emphasis on safety and lung exposure supports the development of next‑generation inhaled therapies.

A portion of the program addresses conditions that are not easily classified, such as rare genetic disorders (e.g., ENPP1 deficiency, ABCC6 deficiency) and studies in healthy volunteers to establish baseline safety. These trials provide essential data for future disease‑specific research.

• ENPP1 deficiency
• ABCC6 deficiency (Pseudoxanthoma elasticum)
• General safety studies in healthy participants
• Pharmacokinetic bridging studies
• Drug‑drug interaction assessments

Though diverse, these early investigations lay the groundwork for targeted therapies across multiple therapeutic domains.